Immuron (NASDAQ:IMRN – Get Free Report) shares fell 2.2% during mid-day trading on Friday. The stock traded as low as $0.78 and last traded at $0.8312. Approximately 11,605 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 27,810 shares. The stock had previously closed at $0.8499.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immuron in a report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.
Read Our Latest Report on Immuron
Immuron Price Performance
The firm has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $1.01.
Immuron (NASDAQ:IMRN – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $1.27 million for the quarter.
Immuron Company Profile
Immuron Limited is a biopharmaceutical company focused on developing and commercializing orally delivered antibody-based therapies for gastrointestinal and immune-related conditions. The company’s technology uses hyperimmune bovine colostrum to produce antibodies designed to bind targeted pathogens or disease-associated molecules in the gastrointestinal tract.
Immuron’s primary commercial product is Travelan, an oral immunotherapy intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC).
Further Reading
- Five stocks we like better than Immuron
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Immuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron and related companies with MarketBeat.com's FREE daily email newsletter.
